iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Alembic Pharma gets USFDA tentative nod for Dronedarone Tablets

10 Jan 2022 , 01:49 PM

Alembic Pharmaceuticals

Alembic Pharmaceuticals Limited on Monday has announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Dronedarone Tablets USP, 400 mg.

The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Multaq Tablets, 400 mg, of Sanofi-Aventis U.S: LLC (Sanofi-Aventis).

Dronedarone is indicated to reduce, the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.

Dronedarone Tablets USP, 400 mg have an estimated market size of US$ 500 million for twelve months ending September 2021, according to IQVIA. Alembic has settled the case with Sanofi-Aventis and will launch its generic as per the terms of settlement.

Alembic has received year to date (YTD) 19 approvals (13 final approvals and 6 tentative approvals) and a cumulative total of 158 ANDA approvals (136 final approvals arid 22 tentative approvals) from USFDA.

At around 1:49 PM, Alembic Pharmaceuticals was trading at Rs822.05 apiece up by Rs15.3 or 1.9% on Sensex.

Related Tags

  • Alembic Pharmaceuticals
  • Alembic Pharmaceuticals Ltd
  • Alembic Pharmaceuticals Ltd approval
  • Alembic Pharmaceuticals Ltd market
  • Alembic Pharmaceuticals Ltd news
  • Alembic Pharmaceuticals Ltd shares
  • Alembic Pharmaceuticals Ltd stocks
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.